Steven Pomerantz

Title: Steven Pomerantz: Innovator in Immunotherapy

Introduction

Steven Pomerantz, an accomplished inventor based in Spring House, PA, has made significant contributions to the field of immunotherapy. His innovative work focuses on developing bispecific binding agents that target specific antigens involved in prostate cancer treatment.

Latest Patents

Pomerantz holds a patent for "Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof". This patent features isolated CD3×PSMA bispecific antigen-binding molecules, where one domain specifically binds to human PSMA and another binds to CD3. The patent also covers fusion proteins and related polynucleotides that encode these proteins, as well as the methods of using the developed bispecific antigen-binding agents.

Career Highlights

Steven Pomerantz is associated with Janssen Biotech, Inc., a company renowned for its biopharmaceutical innovations. His work in the field has played a pivotal role in advancing therapeutic options for patients suffering from prostate cancer.

Collaborations

Throughout his career, Pomerantz has collaborated with notable colleagues such as Glenn Mark Anderson and Rosa Cardoso. These collaborations have fostered a dynamic research environment, enhancing the pursuit of innovative solutions in cancer treatment.

Conclusion

Steven Pomerantz stands out as a distinguished inventor in the realm of immunotherapy. His patented technologies represent a vital step forward in the search for effective treatments for prostate cancer, showcasing his commitment to advancing medical science through innovation.